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ABSTRACT 
GLP-1 and GIP promote insulin secretion from pancreatic β-cells by inducing intracellular signals such as Ca2+ and 
cAMP. Metformin primarily acts by inhibiting glucogenesis in the liver and promoting glucose metabolism in the mus-
cle. It is used as a concomitant drug with the incretin in the treatment of T2D. We focused on intracellular signals under 
various glucose concentrations and assessed the effects of metformin on incretin signaling in MIN6 β-cells. Metformin 
inhibited incretin-induced [Ca2+]i in the presence of 5.5 mM glucose but not 16.7 mM glucose. In accordance with low 
[Ca2+]i, insulin secretion from MIN6 cells declined, despite enhanced incretin-induced cAMP production. Abundant 
expressions of Adcy 6 and 9, which are negatively controlled by Ca2+ signals, were detected in MIN6 cells. Thus, in-
creasing cAMP production was associated with the inhibition of Ca2+ mobilization by metformin. However, we show 
that metformin controls insulin secretion by inhibiting incretin-mediated [Ca2+]i under normoglycemic conditions. 
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1. Introduction 
Metformin is commonly used in the treatment of type 2 
diabetes and improves insulin sensitization and glucose 
metabolism [1]. Metformin acts mainly by inducing liver 
and skeletal muscle serine/threonine kinase B1 (LKB1), 
which activates AMP-activated protein kinase (AMPK) 
by phosphorylating Thr 172 of the AMPK α chain [2]. 
However, in cell free assays, metformin activated LKB1 
and AMPK by an indirect mechanism, and failed to in- 
duce phosphorylation of AMPK [3]. In another study, 
over expression of AMPK in MIN6 cells, which is pan- 
creatic mouse β cell lines established from insulinomas, 
inhibited insulin secretion in the presence of high glucose 
concentrations [4]. The incretin peptides GLP-1 (gluca- 
gon-like peptide 1) and GIP (glucose-dependent insuli- 
notropic polypeptide), which are the gut derived hor- 
mones secreted by L cells and K cells, respectively, after  
nutrient ingestion, are blood glucose-lowering hormones 
that potentiate insulin secretion in response to glucose [5]. 
Receptors of these incretins, GLP-1R and GIPR are G 
protein-coupled receptors (GPCR) that activate the clas- 
sical signaling cascade through Gs and adenylate cyclase 
(Adcy), leading to increased cAMP production [6,7]. 
Incretins can also mobilize stored Ca2+ in intracellular 
organelles by activating ryanodine (RYR) [8] and inosi- 
tol 1, 4, 5-trisphosphate receptors (IP3R) [9]. These two 
small molecules, cAMP and Ca2+, are critical for incretin 
signaling. Reportedly, metformin can inhibit the activi- 
ties of liver Adcy enzymes [10], which include 9 mem- 
brane proteins (Adycs 1 to 9) and one soluble protein 
(Adcy 10) and produce cAMP from ATP at the plasma 
membrane. Several signaling molecules, such as Ca2+, 
calmodulin, protein kinase C (PKC), calcineurin (CaN), 
and G proteins, participate in the regulation of Adcys. 
Adcys 5 and 6 are directly inhibited by Ca2+ [11,12], 
whereas Adcys 1 and 8 are activated by Ca2+-CaM bind-  *Corresponding author. 
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ing [13,14]. As a regulator of endoplasmic reticulum (ER) 
Ca2+ mobilization, cAMP promotes insulin granule exo- 
cytosis [9,15]. Protein kinase A (PKA) and cAMP-acti- 
vated exchange proteins (EPAC), which are cAMP bind- 
ing signal proteins, play central roles in these mecha- 
nisms [15-17]. Hence, Ca2+ and cAMP can mutually 
regulate each other under various conditions. In the pre- 
sent study, we examined the responses of these two small 
molecules to incretins and assessed the actions of met- 
formin against incretin signaling. In addition, we as- 
sessed the expression of the key metformin responsive 
protein LKB1. 
2. Material and Methods 
2.1. Maintenance of the MIN6 β Cell Line 
MIN6 cells were provided by Dr. J. Miyazaki and were 
cultured in high-glucose (25 mM glucose) DMEM con- 
taining 10% fetal bovine serum (FBS), streptomycin, and 
penicillin according to the provider’s procedure [18]. 
2.2. Measurement of cAMP Production 
MIN6 cells were transfected with 3 µg of pGloSensor™ 
20F cAMP plasmid (cAMP sensor protein expression 
vector; Promega KK., WI, USA) per 2 × 106 cells using 
Neon™ Transfection System (Life technologies Co., CA, 
USA), and 3 × 105 transfected cells were seeded into 96 
well white plates. Cells were incubated in DMEM con- 
taining 0.1% bovine serum albumin (BSA) at 37˚C for 
two days, and the medium was replaced with medium 
containing indicated concentrations of metformin. After 
culturing for 2 h, the medium was replaced with CO2- 
independent equilibration medium (Life Technologies Co, 
Carlsbad, CA) containing 6% v/v GloSensor™ cAMP 
reagent (Promega) and 0.1% BSA according to the 
manufacturer’s instructions. Cells were incubated at room 
temperature for a further 2 h and stimulated with 10 nM 
GLP-1 or GIP in HEPES-buffered saline (HBSS) con- 
taining 107 mM NaCl, 6 mM KCl, 1.2 mM MgSO4, 2 
mM CaCl2, 1.2 mM KH2PO4, 20 mM HEPES, and 5.5 or 
16.7 mM glucose at pH 7.4. Luminescence was sequen- 
tially measured using a Varioskan Flash (Thermo Fisher 
Scientific Inc., MA, USA). Data were corrected for basal 
luminescence and mean ± standard deviation (SD) lumi- 
nescence per well were calculated and presented. 
2.3. Measurement of Intracellular Ca2+  
Concentrations 
Two glass coverslips (3 × 10 mm, thickness 0.12 - 0.17 
mm; Matsunami Glass Inc., Osaka, Japan) were set on 24 
well plates before seeding and culturing MIN6 cells in 
DMEM supplemented with 10% FBS in a humidified 
atmosphere with 5% CO2 at 37˚C overnight. Medium 
was then replaced with DMEM containing 0.1% BSA 
and indicated concentrations of metformin, and cells 
were incubated at 37˚C for 2 h. Subsequently, the cal- 
cium indicator Fura-2 AM (5 µM) was added and cells 
were incubated for 40 min in DMEM supplemented with 
1% FBS. Cells on coverslips were washed and perfused 
with HBSS containing 10 nM GLP-1 and GIP. Cytosolic 
Ca2+ concentrations were measured using a 2-wavelength 
excitation method (340 nm/380 nm) according to the pre- 
vious report [19] and mean background was subtracted 
from each value. Data are presented as mean ± SD peak 
delta ratios. 
2.4. Insulin Secretion Analysis 
MIN6 cells were seeded into 48 well plates and were 
cultured to 60% - 70% confluence. Prior to treatment, 
medium was replaced and supplemented with 0.1% BSA, 
and cells were incubated at 37˚C overnight. Subsequently, 
the medium was replaced with fresh medium containing 
0.1% BSA and indicated concentrations of metformin, 
and cells were incubated for 2 h at 37˚C. Medium was 
then replaced with HBSS containing 8 mM glucose and 
0.1% BSA, and the cells were incubated for 40 min at 
37˚C. After washing with PBS, cells were incubated in 2 
mM Ca2+ buffer containing 5.5 or 16.7 mM glucose, 
0.1% BSA, and 10 nM GLP-1 or GIP for 60 min at 37˚C. 
Supernatants were collected for insulin analysis and cells 
were lysed for total protein determinations. Supernatant 
insulin concentrations were measured using a Mouse 
Insulin ELISA KIT (TMB; AKRIN-011T, Shibayagi, 
Gunma, Japan). Data were expressed relative to total pro- 
tein concentrations of lysates. 
2.5. Western Blotting 
MIN6 cells were seeded into 12 well plates and were cul- 
tured to 60% - 70% confluence. Prior to treatment, the 
medium was replaced and supplemented with 0.1% BSA, 
and cells were incubated at 37˚C overnight. Medium was 
then replaced with new medium containing 0.1% BSA, 
and cells were incubated for 10 min. Subsequently, indi-
cated concentrations of metformin were added and cells 
were incubated at 37˚C for indicated times. Supernatants 
were removed and treatments were stopped by the addi- 
tion of 50 µL lysis buffer containing PhosSTOP and 
Complete (Roche Diagnostics, Mannheim, Germany). 
Lysates were sonicated and centrifuged for 5 min at 
15,000 rpm at 4˚C. Protein concentrations were deter- 
mined using a BCA protein assay (Thermo Fisher Scien- 
tific) and 60 µg of protein/lane were separated by SDS- 
PAGE using e-PAGEL (ATTO Co., Tokyo, Japan) and 
were electro transferred onto nitrocellulose membranes 
using a Trans-Blot Turbo Transfer System (Bio-Rad 
Laboratories Inc., Hercules, CA) for 30 min at 25 V. 
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Membranes were then probed with the following mono- 
clonal antibodies: phospho-LKB1 (Ser 428) rabbit mAb 
(C67A3; Cell Signaling Tech., Danvers, MA), LKB1 
mouse mAb (Ley 37D; CNIO, Madrid, Spain), and β- 
actin mouse mAb (AC-15; Abcam plc, Cambridge, UK). 
Immunoreactive bands were visualized using an HRP- 
labeled secondary antibody and enhanced chemilumine- 
scence. Protein bands were quantitated by densitometric 
analysis using the GS-800 instrument (Bio-Rad). 
2.6. Quantitative PCR 
Total RNA was isolated from MIN6 cells using RNAiso 
Plus reagent (Takara Bio Inc., Shiga, Japan), and 2-µg 
aliquots were converted into cDNA using an Applied 
Biosystems High Capacity cDNA Reverse Transcription 
Kit (Life Technologies Co, Carlsbad, CA). Expression of 
Adcy 1 (NM_009622.1), Adcy 2 (NM_153534.2), Adcy 3 
(NM_138305.3), Adcy 4 (NM_080435.1), Adcy 5 (NM_ 
001012765.4), Adcy 6 (NM_007405.2), Adcy 7 (NM_ 
001037723.3), Adcy 8 (NM_009623.2), Adcy 9 (NM_ 
009624.2), and β-actin (NM_007393.3) mRNAs were 
determined by real-time PCR using an Applied Biosys- 
tems TaqMan Fast Universal Master Mix and gene spe- 
cific TaqMan primer probe sets (Adcy 1, Mm01187829_ 
m1; Adcy 2, Mm00467874_m1; Adcy 3, Mm00460371_ 
m1; Adcy 4, Mm00475491; Adcy 5, Mm00674122_m1; 
Adcy 6, Mm 00475772_m1; Adcy 7, Mm00545780_m1; 
Adcy 8, Mm00507722_m1; Adcy 9, Mm 00507743_m1; 
and β-actin, 4352933E). Fluorophore-based detection 
using TaqMan probes forms the basis for real-time 
monitoring. Realtime PCR was performed using an Ap- 
plied Biosystems STEP ONE thermal cycler. Data were 
normalized to the expression of β-actin. 
2.7. Statistics 
Statistical comparisons were performed with simple main 
effect test, or ANOVA with Bonferroni/Games—Howell 
post-hoc tests, as appropriate. Results are presented as 
means ± SD. All statistical analyses were performed us- 
ing SPSS for Windows (SPSS Inc., Chicago, Ill., USA). 
3. Results 
3.1. Increasing cAMP Production in Response to 
Metformin-Induced GLP-1 and GIP 
MIN6 cells were treated with 10 nM GLP-1 or GIP in the 
presence of 5.5 or 16.7 mM glucose, and cAMP produc- 
tion was monitored for 40 min (Figures 1(a) and (b)). 
Pretreatment with metformin for 2 h significantly en- 
hanced incretin-induced cAMP production by 1.7-fold in 
the presence of 5.5 mM glucose, but this was not met- 
formin dose-dependent. In contrast, in the presence of 
16.7 mM glucose, metformin had no effect on incretin- 
induced cAMP production. These data suggest that met- 
formin positively regulates incretin-induced cAMP pro- 
duction in normoglycemic conditions. 
3.2. Modulation of GLP-1-Mediated [Ca2+]i by 
Metformin 
MIN6 cells were stimulated with 10 nM GLP-1 or GIP in 
the presence of 5.5 or 16.7 mM glucose. Immediate in- 
creases in [Ca2+]i were observed (Figure 2), particularly 
with GLP-1 under both glucose concentrations, whereas 
in the absence of added glucose, the response was sig- 
nificantly lower (data not shown). Nonetheless, even in 
the absence of added glucose, glibenclamide induced a 
Ca2+ delta ratio response of 0.423 ± 0.321 (diffuse SD 
value caused by the different oscillation timing of indi- 
vidual cells) by binding the sulfonylurea receptor and 
activating L-type voltage dependent Ca2+ channels 
(VDCC; data not shown). Given the small Ca2+ response 
to GIP, we analyzed the mechanisms of GLP-1-induced 
[Ca2+]i. In the presence of 5.5 mM glucose, GLP- 
1-mediated increments of [Ca2+]i were reduced to ap- 
proximately 20% after pre-treatment with 1 mM met- 
formin (p < 0.05, Figure 2(a)), but were not decreased in 
the presence of 16.7 mM glucose (Figure 2(b)). More- 
over, this decreased depended on pre-incubation time 
with metformin, with a maximum inhibitory effect after 2 
h (p < 0.05, Figure 2(c)). In the presence of 5.5 mM glu- 
cose, treatment with 1 mM metformin and 10 nM GLP-1 
did not result in decreased [Ca2+]i responses (Figure 
2(a)). 
3.3. Effects of Metformin on GLP-1- and  
GIP-Induced Insulin Secretion 
Treatment with 10 nM GLP-1 or GIP enhanced insulin 
secretion in the presence of 5.5 mM glucose (Figure 3), 
whereas 2 h-pretreatment with >100 μM metformin 
blocked this effect in the presence of 5.5 mM glucose, no 
effect of metformin was observed in the presence of 16.7 
mM glucose (Figure 3(a)). Furthermore, 2 h-pretreat- 
ment with >10 μM metformin significantly reduced GIP- 
induced insulin secretion in the presence of 5.5 mM glu- 
cose, but not in the presence of 16.7 mM glucose (Figure 
3(b)). These data corroborate the inhibition of Ca2+ re- 
sponses by metformin and suggested that Ca2+ plays a 
more critical role in insulin secretion than cAMP. 
3.4. Activation of LKB1 by Metformin 
Metformin is known to induce phosphorylation of LKB1 
at Ser 428. Thus, we determined LKB1 phosphorylation 
following treatment with metformin and observed peak 
LKB1 phosphorylation after treatment with >10 µM met- 
formin for 60 min (p < 0.05; Figures 4(a) and (b)). Ve- 
hicle alone (None) induced LKB1 phosphorylation but  
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Figure 1. The influence of metformin on cAMP production in MIN6 cells treated with 10 nM GLP-1 or GIP in the presence of 
5.5 (a) or 16.7 mM glucose (b). MIN6 cells were stimulated with 10 nM GLP-1 or GIP in HBSS after 2 h-pretreatments with 0 
μM (circle), 10 µM (triangle), 100 µM (rhombus), or 1 mM metformin (square), and luminescence was measured for 40 min. 
Luminescence at 20 min is shown in bar graphs. All data were reproduced in 3 - 5 independent experiments. Data are pre-
sented as mean ± SD and differences were identified using ANOVA with Bonferroni post-hoc test. Met; metformin. 
 
 
Figure 2. Effect of metformin on Ca2+ responses to 10 nM GLP-1 in MIN6 in the presence of 5.5 (a) or 16.7 mM glucose (b). 
MIN6 cells were perfused with HBSS containing 10 nM GLP-1, and cytosolic Ca2+ concentrations were measured using a 2- 
wavelength excitation method (340/380) for 10 min (solid line of left panel). MIN6 cells were pretreated with 1 mM metformin 
for 2 h (thin dotted line of left panel) or simultaneously with 10 nM GLP-1 (thick dotted line of left panel). Delta ratios of 
each peak are presented in bar graphs. The effects of pretreatment with metformin from 30 - 180 min were analyzed (c). Data 
are presented as mean ± SD of 2 - 3 independent experiments and differences between treatment groups were identified using 
ANOVA with Games-Howell test. Met, metformin; sim, simultaneously; pre, pretreatment; Glu, glucose. 
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Figure 3. Effect of metformin on insulin production in MIN6 cells treated with GLP-1 (a) or GIP (b) in the presence of 5.5 or 
16.7 mM glucose. After 2 h-pretreatment with metformin at 0, 10, 100, or 1000 μM, culture medium was changed to HBSS 
containing 8 mM glucose, and MIN6 cells were incubated for a further 40 min. Medium was then removed and MIN6 cells 
were stimulated with 10 nM GLP-1 or GIP in HBSS for 60 min. Data are presented as mean ± SD of 3 - 4 independent ex-
periments. Differences between treatment groups were identified using ANOVA with Games-Howell (a) or Bonferroni (b) 
post-hoc tests. 
 
the peak response was at 120 min. It suggested that vehi- 
cle lacking nutrition caused ATP production through 
activating LKB1-AMPK pathway and metformin could 
enhance the signaling. 
3.5. Quantification of Adenylate Cyclase mRNA  
Expression 
Adenylate cyclases synthesize cAMP from ATP; there- 
fore, we analyzed mRNA expression of adenylate cy- 
clases (1 to 9) in MIN6 cells. Real-time PCR data 
showed that Adcy 6 and 9 were expressed at much higher 
levels in MIN6 cells than the other isoforms (Figure 
4(c)). 
4. Discussion 
Metformin is widely used as concurrent treatment for 
type 2 diabetes mellitus and causes few serious adverse 
reactions, even at high doses. Its pharmacological actions 
on glucose metabolism involve the LKB1-AMPK path- 
way, which appears to activate ataxia-telangiectasia mu- 
tants and activation-induced cytidine deaminase (ATM) 
[20]. Several other actions of metformin that are inde- 
pendent of glucose metabolism have been reported. Spe- 
cifically, metformin attenuates neointimal hyperplasia by 
inhibiting smooth muscle cell proliferation and migration 
through the insulin-signaling pathway by inhibiting the 
expression of advanced glycation end product (AGEs) 
receptors, which are related to cancer mortality through 
AMPK [21,22]. A recent report demonstrates that ad- 
ministration of metformin increased mRNA expression 
of the receptors GLP-1R and GIPR in mice. Moreover, in 
vitro metformin treatments enhanced GLP-1R and 
PPAR-α expression in INS-1 rat β-cells [23]. In this 
study, GLP-1R expression increased with that of perox- 
isome proliferator-activated receptor-α (PPAR-α). How- 
ever, our in vitro analysis in MIN6 cells showed that ex- 
pression of PPAR-α, GLP-1R, and GIPR were reduced 
after 24-h treatments with 1-mM metformin in the pres- 
nce of 5.5 mM glucose (data not shown). MIN6 and  e 
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Figure 4. Analysis of LKB1 activation and Adcys mRNA expression in metformin-treated MIN6 cells. (a) MIN6 cells were 
treated with 1 mM metformin for 30, 60, or 120 min. After treatment with metformin, cell lysates (60 μg/lane) were electro- 
phoresed and blotted, and protein bands were visualized using chemiluminescence. Typical blots from 2 - 3 independent ex- 
periments are presented, and bar graphs show the mean ± SD of 2 - 3 independent experiments; (b) Metformin dose-de- 
pendency was analyzed at 0, 10, 100, and 1000 μM; (c) Adcys 1 - 9 were quantified by real-time PCR using the TaqMan 
method. Data are presented as the mean ± SD of 2 experiments conducted in triplicate. Differences between treatment groups 
were identified using simple main effect test (a) and ANOVA with Bonferroni post-hoc test (b). Met, metformin; Adcy, ade- 
nylate cyclase. 
 
INS-1 cells are commonly cultured in high glucose me- 
dium (25 and 11.1 mM, respectively). Differences be- 
tween INS-1 and MIN6 cells may reflect their respective 
glucose requirements.  
GLP-1 facilitates Ca2+-induced Ca2+ release (CICR), 
which is mediated by opening of IP3R and RYR cell 
membrane channels. Holz et al. clearly demonstrated that 
GLP-1-stimulated cAMP was required for activation of 
CICR by the cAMP binding proteins PKA and EPAC. 
Moreover, CICR requires continual activation of VDCCs 
by Ca2+ within intracellular microdomains, but not by 
robust Ca2+ influx from extracellular spaces [8,15,17,24]. 
Accordingly, the Ca2+ efflux response to GLP-1 was 
lower than that induced by glibenclamide, presumably 
because glibenclamide induces robust Ca2+ influx by 
opening VDCCs. In the present study, metformin pre- 
treatment inhibited GLP-1-induced CICR and inhibited 
Ca2+ mobilization and consequent insulin secretion under 
normoglycemic conditions. However, under hypergly- 
cemic conditions, metformin did not affect either Ca2+ or 
cAMP responses to incretin signals. In contrast, met- 
formin enhanced cAMP production by GLP-1 and GIP 
under normoglycemic condition. Although cAMP is gen- 
erally considered a positive signal for Ca2+ mobilization, 
the present data indicated that elevated [Ca2+]i is indis- 
pensable for insulin secretion. Since submicromolar Ca2+ 
inhibits the functions of Adcys such as Adcy 5, 6, and 9 
[25], cAMP production by these Adcys is enhanced when 
intracellular Ca2+ is depleted. Real-time PCR data 
showed that the major isoforms expressed in MIN6 cells 
are Adcy 6 and 9, suggesting that low intracellular Ca2+ 
levels block inhibition of Adcys. Moreover, metformin 
enhanced cAMP production and inhibited incretin-in- 
duced CICR signaling. Kitaguchi et al. showed that ex- 
tracellular Ca2+ influx-activated Adcy 1 played an impor- 
tant role in insulin secretion following stimulation with 
25 mM glucose [26]. High concentrations of glucose 
activate the KATP-VDCC axis by increasing ATP produc- 
tion, and subsequent Ca2+ influx possibly activates Adcy 
1. Figure 4(c) shows that Adcys 6 and 9 were the domi- 
nant isoforms in MIN6 cells and that Adcy 1 expression 
was very low. We speculated that incretin-induced 
cAMP production was dependent on Adcys 6 or 9 under 
normo-glycemic conditions.  
Treatment with metformin activated LKB1 with a peak 
response at 60 min. Pretreatment with metformin for 2 h 
also inhibited the Ca2+ response to incretin, with weak 
inhibition at 60 min. Temporal differences between acti- 
vation of LKB1 and inhibition of the incretin-induced 
Ca2+ response were observed after treatments with met- 
formin, suggesting that activation of LKB1 precedes 
downstream signals. However, the regulatory mecha- 
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nisms of Ca2+ mobilization by metformin remain obscure, 
and further investigations are required to confirm the 
causal relationship with LKB1. Nonetheless, the present 
data support mimicry of the physiological function of 
circulating adiponectin by metformin, which controls 
incretin-mediated hypoglycemic episodes. 
5. Conclusion 
Metformin has been proven efficacy in the treatment of 
type 2 diabetes mellitus. Our data indicate a novel func-
tion of metformin as a modulator of incretin-mediated 
insulin secretion. Using in vitro analyses, we initially 
demonstrated incretin-induced insulin secretion under 
normoglycemic conditions and showed that suppression 
of this cascade by metformin is blocked in hyperglyce-
mic conditions. We assert that this effect of metformin 
should be taken into consideration during incretin treat-
ments for the control of blood glucose concentrations. 
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